Creating a database for ovarian and related cancers
Official title: Development of a Prospective and Monocentric Cinical and Biological Database in Epithelial Ovarian Cancer, Fallopian Tube Cancer and Primitive Peritoneal Cancer
Run by Institut du Cancer de Montpellier - Val d'Aurelle · NCT03976999 · Data updated 2026-11-12
This study is creating a detailed database for patients with ovarian and related cancers to help researchers find better treatments and understand the disease more deeply.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Institut du Cancer de Montpellier - Val d'Aurelle Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Montpellier) |
| Status | Recruiting |
| Started | July 5, 2017 |
| Main results expected | July 2027 |
| Study ends | July 2032 |
| Registry record updated | February 12, 2025 |
| Trial ID | NCT03976999 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 or older who have been diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primitive peritoneal cancer and are eligible for surgery and chemotherapy.
✕Probably not a fit
Patients who are pregnant, nursing, or unable to participate in regular follow-up due to psychological, familial, social, or geographical reasons may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to develop a comprehensive clinical and biological database specifically for patients diagnosed with epithelial ovarian cancer, fallopian tube cancer, and primitive peritoneal cancer. The database will include blood and tissue samples along with clinical data to enhance understanding of these cancers and facilitate the development of new treatments. Researchers will utilize this resource to identify predictive factors for treatment responses, prognostic markers, and optimize diagnostic tests. The ultimate goal is to create robust preclinical models for testing alternative therapies and discovering new biomarkers.
Why it matters
Potential benefit: If successful, this initiative could lead to improved treatment strategies and outcomes for patients with ovarian and related cancers.
How similar studies have gone: While this approach is not widely tested, similar initiatives in cancer research have shown promise in enhancing treatment development and patient outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 or older * Patient at the diagnosis of an epithelial ovarian cancer, or a fallopian tube caner or a primitive peritoneal cancer * Patient eligible for, at least, one surgery and a chemotherapy * Patient having given his informed, written and express consent Exclusion Criteria: * Patient not affiliated to a social protection scheme * Pregnant and / or nursing women * Subject under tutelage, curatorship or safeguard of justice * Patient whose regular follow-up is impossible for psychological, familial, social or geographical reasons
Where it's running
-
ICM - Institut régional du Cancer Montpellier
Montpellier, France Recruiting
Study contacts
- Principal investigator: COLOMBO Pierre-Emmanuel, M.D — ICM - Institut régional du Cancer Montpellier
- Study coordinator: Aurore MOUSSION
- Email: DRCI-icm105@icm.unicancer.fr
- Phone: +33 4 67 61 31 02
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sofetabart Mipitecan (LY4170156) versus standard chemotherapy for platinum-resistant and platinum-sensitive high-grade ovarian, fallopian tube, and primary peritoneal cancer
This trial tests whether the targeted drug Sofetabart Mipitecan can better shrink tumors or delay progression than standard chemotherapies for people with platinum-resistant or platinum-sensitive high-grade ovarian, fallopian tube, or primary peritoneal cancer.
-
Testing BP1001-A for advanced or recurrent solid tumors
This study is testing a new drug called BP1001-A to see if it can safely help people with advanced or recurring solid tumors when used alone or with another medication called paclitaxel.
-
Using letrozole as maintenance therapy for ovarian cancer
This study is testing if adding letrozole to standard treatment helps women with estrogen-receptor positive ovarian cancer live longer without their cancer getting worse after surgery and chemotherapy.
-
Combination treatment for advanced ovarian cancer
This study is testing a new combination of medications for people with advanced ovarian cancer to see if it helps them feel better and stay healthier longer.
-
Comparing open and robotic surgery for women with complex pelvic masses
This study is testing whether open surgery or robotic surgery is better for women with suspicious pelvic masses that are 8 cm or smaller.
-
Personalized cancer therapy for ovarian cancer patients
This study is testing if personalized treatment plans based on tumor profiles can help newly diagnosed ovarian cancer patients who have limited options feel better and have better outcomes than just standard chemotherapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.